AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
AbbVie (ABBV) shares rise on earnings beat - prepared for loss of Humira exclusivity
February 9, 2023 10:00 AM ESTAbbVie (NYSE: ABBV) shares are up more than 3% in early Thursday trading after the company topped earnings estimates for the fourth quarter.
Earnings came in at $3.60 per share, $0.07 better than the analyst estimate of $3.53. However, the biotech firm missed the analyst consensus revenue forecast of $15.33 billion, coming in at $15.12 billion.
The company's results included an unfavorable impact of $0.13 per share related to the fourth-quarter 2022 acquired IPR&D and milestones expense.
The... More
AbbVie (ABBV) Tops Q4 EPS by 7c, Offers Guidance
February 9, 2023 7:46 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $3.60, $0.07 better than the analyst estimate of $3.53. Revenue for the quarter came in at $15.12 billion versus the consensus estimate of $15.33 billion.
These Results Include an Unfavorable Impact of $0.13 Per Share Related to Fourth-Quarter 2022 Acquired IPR&D and... More